Fig. 6.
Recipient immunization with a tumor cell vaccine increases GVT activity against preexisting 205 tumor.
One month after SW→ B6 BMT, micrometastatic fibrosarcoma was established by intravenous injection of 1 × 105 205 tumor cells. Recipients were either not immunized (nonimmune) or immunized 4 times with 50 Gy-irradiated 205IL-2/TK cells (205-immune) at a weekly interval starting on day 3 after challenge. Lung nodules were counted 1 month after tumor challenge. The day 3 205-immune group had a significant reduction in lung nodules (P = .0140) compared to the nonimmune recipients.
